The agency has approved nintedanib (Ofev) to slow the rate of pulmonary function decline in adult patients with interstitial lung disease associated with systemic sclerosis or scleroderma.
The FDA has approved the first treatment for patients with a rare type of lung disease. Late last week, the agency approved nintedanib (Ofev) to slow the rate of pulmonary function decline in adult patients with interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD).
Scleroderma, which impacts approximately 100,000 people in the United States, causes tissue throughout the body, including in the lungs, to thicken and scar. ILD is one of the most common manifestations of scleroderma, impacting nearly half of those with the disease. For patients with SSc-ILD, lung function declines over time, which can be debilitating and life threatening.
“Patients suffering from scleroderma need effective therapies, and the FDA supports the efforts of drug companies that are designing and conducting the clinical trials necessary to bring treatment options to scleroderma patients,” said Nikolay Nikolov, MD, associate director for Rheumatology of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research, in a statement.
The effectiveness of nintedanib was demonstrated in a trial of 576 patients aged 20 to 79 years with the disease who were treated for at least 52 weeks; some were treated for up to 100 weeks. Compared with those taking placebo, patients who took nintedanib had less lung function decline, with the drug slowing the loss of pulmonary function by 44%.
The safety profile of the drug observed throughout the study was consistent with that known of the therapy. The most frequently reported serious adverse event was pneumonia (2.8% for nintedanib vs 0.3% for placebo). Approximately one-third of patients taking nintedanib had adverse reactions leading to dose reductions compared with 4% of those taking placebo.
“An approved anti-fibrotic medication for this condition is a scientific advancement in the care of patients living with this rare disease,” Kristin Highland, MD, a pulmonologist at the Cleveland Clinic, said in a statement. “The option to offer a new therapy is welcome news for doctors and their patients.”
Prescribing information for the drug includes warnings for patients with moderate or severe liver impairment, patients with elevated liver enzymes and drug-induced liver injury, and patients with gastrointestinal disorders. The FDA also warned that nintedanib could also cause embryo-fetal toxicity that can result in fetal harm, blood clots, bleeding, and gastrointestinal perforation.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More